KURN Stock Overview
Kuros Biosciences AG, a biopharmaceutical company, engages in the commercialization and development for tissue repair and bone regeneration in the United States, the European Union, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Kuros Biosciences AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF8.12 |
| 52 Week High | CHF8.40 |
| 52 Week Low | CHF1.11 |
| Beta | 0.91 |
| 1 Month Change | 57.98% |
| 3 Month Change | 85.81% |
| 1 Year Change | 549.60% |
| 3 Year Change | 286.67% |
| 5 Year Change | 224.80% |
| Change since IPO | -72.93% |
Recent News & Updates
Why Investors Shouldn't Be Surprised By Kuros Biosciences AG's (VTX:KURN) 35% Share Price Surge
Apr 11
Some Confidence Is Lacking In Kuros Biosciences AG (VTX:KURN) As Shares Slide 29%
Jan 03Recent updates
Why Investors Shouldn't Be Surprised By Kuros Biosciences AG's (VTX:KURN) 35% Share Price Surge
Apr 11Some Confidence Is Lacking In Kuros Biosciences AG (VTX:KURN) As Shares Slide 29%
Jan 03Companies Like Kuros Biosciences (VTX:KURN) Are In A Position To Invest In Growth
Dec 17We Think Kuros Biosciences (VTX:KURN) Can Afford To Drive Business Growth
Sep 17Market Cool On Kuros Biosciences AG's (VTX:KURN) Revenues
Jun 28Here's Why We're Not At All Concerned With Kuros Biosciences' (VTX:KURN) Cash Burn Situation
May 03Companies Like Kuros Biosciences (VTX:KURN) Are In A Position To Invest In Growth
Jun 11Shareholders May Find It Hard To Justify Increasing Kuros Biosciences AG's (VTX:KURN) CEO Compensation For Now
Apr 12Reflecting on Kuros Biosciences' (VTX:KURN) Share Price Returns Over The Last Five Years
Mar 02What We Learned About Kuros Biosciences' (VTX:KURN) CEO Pay
Nov 17
Shareholder Returns
| KURN | CH Biotechs | CH Market | |
|---|---|---|---|
| 7D | 7.4% | -3.1% | -0.9% |
| 1Y | 549.6% | 11.6% | -4.0% |
Return vs Industry: KURN exceeded the Swiss Biotechs industry which returned 11.6% over the past year.
Return vs Market: KURN exceeded the Swiss Market which returned -4% over the past year.
Price Volatility
| KURN volatility | |
|---|---|
| KURN Average Weekly Movement | 9.9% |
| Biotechs Industry Average Movement | 7.5% |
| Market Average Movement | 3.5% |
| 10% most volatile stocks in CH Market | 7.4% |
| 10% least volatile stocks in CH Market | 1.9% |
Stable Share Price: KURN's share price has been volatile over the past 3 months.
Volatility Over Time: KURN's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Swiss stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 80 | Chris Fair | www.kuros.ch |
Kuros Biosciences AG, a biopharmaceutical company, engages in the commercialization and development for tissue repair and bone regeneration in the United States, the European Union, and internationally. It operates through three segments: Medical Devices, Pharmaceuticals, and Legacy Portfolio. The company offers MagnetOs Granules, an original advanced bone graft based on the submicron needle-shaped NeedleGrip surface technology; MagnetOs Putty, a mold use to fill bony voids for a predictable fusion; MagnetOs Easypack Putty, a ready-to-use mold to be implanted in any intervertebral disc space or posterolateral spine level; and Magnetos Flex Matrix, an open matrix bone graft.
Kuros Biosciences AG Fundamentals Summary
| KURN fundamental statistics | |
|---|---|
| Market cap | CHF299.21m |
| Earnings (TTM) | -CHF13.73m |
| Revenue (TTM) | CHF33.56m |
8.9x
P/S Ratio-21.8x
P/E RatioIs KURN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KURN income statement (TTM) | |
|---|---|
| Revenue | CHF33.56m |
| Cost of Revenue | CHF10.69m |
| Gross Profit | CHF22.87m |
| Other Expenses | CHF36.60m |
| Earnings | -CHF13.73m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.37 |
| Gross Margin | 68.14% |
| Net Profit Margin | -40.90% |
| Debt/Equity Ratio | 0% |
How did KURN perform over the long term?
See historical performance and comparison